← Back to Search

Stress Testing Protocol for Coronary Heart Disease

N/A
Recruiting
Led By Michael Nelson, PhD
Research Sponsored by Cedars-Sinai Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Must not have
Women who are pregnant
History of cardiovascular, pulmonary, or neurological disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is studying microvascular coronary dysfunction, which is abnormalities in small blood vessels/arteries in the heart, in women.

Who is the study for?
This trial is for men and women over 18 who fully understand and agree to the study's procedures. It excludes pregnant women, those unable to consent, with a history of heart/lung/brain diseases, high blood pressure, diabetes, metal implants or claustrophobia (which affects MRI testing), adherence issues, or animal dander allergies.
What is being tested?
The study tests how different 'stress' activities like handgrip exercises, leg exercises, and altitude simulation affect small blood vessels in the heart using advanced cardiac MRI. It aims to better understand coronary microvascular dysfunction in women with chest pain but no large artery blockages.
What are the potential side effects?
Since this trial involves physical stress tests rather than medication or invasive procedures, side effects may include temporary muscle fatigue or soreness from exercise and discomfort from being in confined spaces during MRI scans.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently pregnant.
Select...
I have a history of heart, lung, or brain disease.
Select...
I have diabetes.
Select...
I am unable to understand and agree to the study's procedures and risks.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: calibrationExperimental Treatment3 Interventions
10 healthy individuals who will help to synchronize our imaging and stress testing maneuvers.
Group II: Women w/microvascular diseaseExperimental Treatment3 Interventions
10 women with microvascular disease
Group III: Normal controlsExperimental Treatment3 Interventions
10 age-matched women with no evidence of microvascular disease

Find a Location

Who is running the clinical trial?

Cedars-Sinai Medical CenterLead Sponsor
512 Previous Clinical Trials
163,334 Total Patients Enrolled
6 Trials studying Nephrotic Syndrome
667 Patients Enrolled for Nephrotic Syndrome
Michael Nelson, PhDPrincipal InvestigatorCedars-Sinai Medical Center

Media Library

Handgrip Clinical Trial Eligibility Overview. Trial Name: NCT02301663 — N/A
Nephrotic Syndrome Research Study Groups: Women w/microvascular disease, calibration, Normal controls
Nephrotic Syndrome Clinical Trial 2023: Handgrip Highlights & Side Effects. Trial Name: NCT02301663 — N/A
Handgrip 2023 Treatment Timeline for Medical Study. Trial Name: NCT02301663 — N/A
~11 spots leftby Dec 2030
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top